SCHEMBL3379566

SCHEMBL3379566

CC(C)(C)OC(=O)N[C@@H](C(=O)O)c1ccc(OCCN2CCOCC2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.53
KDM4E B2RXH2 2/20 0.53
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
SMN1; SMN2 Q16637 2/20 0.51
GAA P10253 1/20 0.51
ACACB O00763 1/20 0.48
HRH3 Q9Y5N1 1/20 0.48
LTA4H P09960 1/20 0.46
EPHX2 P34913 1/20 0.45
HRH2 P25021 1/20 0.45
HRH1 P35367 1/20 0.45
MAPT P10636 1/20 0.45
RECQL P46063 1/20 0.45
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA7 P43166 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3379563 1.00 ALDH1A1 (0.53) ALDH1A1KDM4ENPC1RAB9AMEN1
SCHEMBL3379568 1.00 ALDH1A1 (0.53) ALDH1A1KDM4ENPC1RAB9AMEN1
SCHEMBL3378524 0.92 SMN1; SMN2 (0.51) ALDH1A1KDM4ENPC1RAB9AMEN1
SCHEMBL31737836 0.92 SMN1; SMN2 (0.51) ALDH1A1KDM4ENPC1RAB9AMEN1
SCHEMBL3378528 0.92 SMN1; SMN2 (0.51) ALDH1A1KDM4ENPC1RAB9AMEN1
SCHEMBL3815002 0.91 PSMB1 (0.51) ALDH1A1KDM4EMEN1KMT2AHRH3
SCHEMBL4684740 0.90 PSMB1 (0.53) ALDH1A1KDM4EMEN1KMT2AACACB
SCHEMBL3376479 0.90 HRH2 (0.48) ALDH1A1KDM4ERAB9AMEN1KMT2A
SCHEMBL4684742 0.90 PSMB1 (0.53) ALDH1A1KDM4EMEN1KMT2AACACB
SCHEMBL3376481 0.90 HRH2 (0.48) ALDH1A1KDM4ERAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1989186-B1 HYDANTOIN BASED KINASE INHIBITORS HOFFMANN LA ROCHE (CH) 2010-11-17 EP disclosed
US-7612212-B2 2-[(S)-2-((S)-2,5-dioxo-4-phenyl-imidazolidin-1-yl)-4-methyl-pentanoylamino]-thiazole-4-carboxylic acid methyl ester; mitogen activated protein/extracellular signal regulated kinase kinase inhibitor; anticarcinogenic agent, cognition activator, nervous and autoimmune system disorders HOFFMANN-LA ROCHE INC. (US) 2009-11-03 US disclosed
US-7427635-B2 Substituted hydantoins HOFFMANN-LA ROCHE INC. (US) 2008-09-23 US disclosed
WO-2008101840-A1 COMBINATION OF ERLOTINIB AND MEK-INHIBITORS FOR INHIBITING PROLIFERATION OF TUMOR CELLS F. HOFFMANN-LA ROCHE AG (CH) 2008-08-28 WO disclosed
US-20080207563-A1 METHOD FOR INHIBITING PROLIFERATION OF TUMOR CELLS NIU HUIFENG 2008-08-28 US disclosed
EP-1781649-B1 SUBSTITUTED HYDANTOINS HOFFMANN LA ROCHE (CH) 2008-08-13 EP disclosed
US-20070197617-A1 Substituted hydantoins CHEN SHAOQING 2007-08-23 US disclosed
US-20060041146-A1 Substituted hydantoins HOFFMANN-LA ROCHE AG 2006-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197617-A1 Substituted hydantoins HNMT, HRH3, BRAF ALDH1A1 963/4885KDM4E 923/4885NPC1 2469/4885
US-20060041146-A1 Substituted hydantoins HNMT, MAPK6, KYNU ALDH1A1 552/4885KDM4E 704/4885NPC1 3832/4885
US-20080207563-A1 METHOD FOR INHIBITING PROLIFERATION OF TUMOR CELLS MKI67, BRAF, MYC ALDH1A1 2822/4885KDM4E 3131/4885NPC1 3225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.